World's Best Scientists 2026 revealed!
Nancy F. Olivieri

Nancy F. Olivieri

Overview

Nancy F. Olivieri is affiliated with the University of Toronto in Canada and has contributed to the field of Medicine, particularly focusing on Public Health, Environmental and Occupational Health, Pharmacology, Economics and Econometrics, Genetics, and Hematology.

Their recent research publications exhibit a focus on hemoglobinopathies, pharmaceutical economics, and pharmacovigilance. Notable papers include:

  • Discrepancies in self-reported financial conflicts of interest disclosures by physicians: a systematic review, 2021, BMJ Open
  • Survival and complications in patients with haemoglobin E thalassaemia in Sri Lanka: a prospective, longitudinal cohort study, 2021, The Lancet Global Health
  • Oxidative status in the β-thalassemia syndromes in Sri Lanka; a cross-sectional survey, 2021, Free Radical Biology and Medicine
  • Leg Ulcers: A Report in Patients with Hemoglobin E Beta Thalassemia and Review of the Literature in Severe Beta Thalassemia, 2021, Acta Haematologica
  • Knowledge, Information Sources, and Institutional Trust of Patients Regarding Medication Use in Pregnancy: A Systematic Review, 2021, Journal of Family & Reproductive Health

Their work spans several main research topics, including:

  • Pharmaceutical industry and healthcare
  • Pharmaceutical Economics and Policy
  • Hemoglobinopathies and Related Disorders
  • Iron Metabolism and Disorders
  • Pharmacovigilance and Adverse Drug Reactions
  • Biomedical Ethics and Regulation
  • Healthcare cost, quality, practices

Frequent collaborators in their research projects include:

  • Abirami Kirubarajan
  • Anuja Premawardhena
  • Angela Allen
  • Sachith Mettananda
  • Vikita Mehta

Publications have appeared in diverse venues such as BMJ Open, The Lancet Global Health, Free Radical Biology and Medicine, Acta Haematologica, and the Journal of Family & Reproductive Health, reflecting a broad interdisciplinary approach.

Best Publications

  • Prevention of a First Stroke by Transfusions in Children with Sickle Cell Anemia and Abnormal Results on Transcranial Doppler Ultrasonography

    R J Adams;V C McKie;L Hsu;B Files

  • Iron-chelating therapy and the treatment of thalassemia

    Nancy F. Olivieri;Gary M. Brittenham

  • The β-Thalassemias

    Nancy F. Olivieri

  • Survival in medically treated patients with homozygous beta-thalassemia.

    Nancy F. Olivieri;David G. Nathan;James H. MacMillan;Alan S. Wayne

  • Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment

    Martin H. Steinberg;Martin H. Steinberg;Franca Barton;Oswaldo Castro;Charles H. Pegelow

  • A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

    Maria Domenica Cappellini;Alan Cohen;Antonio Piga;Mohamed Bejaoui

  • A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the β-Globin Disorders

    S. P. Perrine;G. D. Ginder;D. V. Faller;G. H. Dover

  • Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine Infusions

    Olivieri Nf;Buncic;Chew E;Gallant T

  • The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up

    Martin H. Steinberg;William F. McCarthy;Oswaldo Castro;Samir K. Ballas

  • Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.

    Nancy F. Olivieri;Gary M. Brittenham;Christine E. McLaren;Douglas M. Templeton

  • Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions.

    Charles H. Pegelow;Robert J. Adams;Virgil McKie;Miguel Abboud

  • Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

    Eric Nisbet-Brown;Nancy F Olivieri;Nancy F Olivieri;Patricia J Giardina;Patricia J Giardina;Robert W Grady;Robert W Grady

  • Iron-chelation therapy with oral deferiprone in patients with thalassemia major.

    Nancy F. Olivieri;Gary M. Brittenham;Doreen Matsui;Matitiahu Berkovitch

  • Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial.

    Elliott P. Vichinsky;Naomi L.C. Luban;Elizabeth Wright;Nancy Olivieri

  • Secondary Iron Overload

    James P. Kushner;John P. Porter;Nancy F. Olivieri

  • Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.

    Lawrence Wolfe;Nancy Olivieri;Darlene Sallan;Steven Colan

  • Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study

    John Porter;Renzo Galanello;Giuseppe Saglio;Ellis E.J. Neufeld

  • Stroke prevention trial in sickle cell anemia.

    Robert J Adams;Virgil C McKie;Don Brambilla;Elizabeth Carl

  • Bone Disease in Thalassemia: A Frequent and Still Unresolved Problem

    Maria G Vogiatzi;Eric A Macklin;Ellen B Fung;Angela M Cheung

  • Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia

    Martin H. Steinberg;Franca Barton;Oswaldo Castro;Charles H. Pegelow

Frequent Co-Authors

Elliott Vichinsky
Elliott Vichinsky University of California, San Francisco
David J. Weatherall
David J. Weatherall University of Oxford
Gideon Koren
Gideon Koren Brown University
Ellis J. Neufeld
Ellis J. Neufeld Boston Children's Hospital
John B. Porter
John B. Porter University College London
John S. Waye
John S. Waye McMaster University
David H.K. Chui
David H.K. Chui Boston University
Gary M. Brittenham
Gary M. Brittenham Columbia University
David G. Nathan
David G. Nathan Harvard University
Tim E. A. Peto
Tim E. A. Peto University of Oxford

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring Medicine in the USA, there are a range of health care administration online degree options that can open doors to leadership and management roles in healthcare settings. These programs focus on the non-clinical aspects of healthcare, such as policy, ethics, finance, and hospital administration.

For those interested in advanced healthcare leadership, pursuing one of the cheapest mha programs can be an excellent choice. Master’s degrees in healthcare administration are designed for working professionals aiming for senior positions, blending affordability with flexibility through online learning.

Clinical professionals may consider further specialization through cheap dnp online programs. The Doctor of Nursing Practice (DNP) is a practice-focused doctorate that prepares nurses for leadership in clinical practice, policy, and education.

Alternatively, aspiring pharmacists can benefit from reputable pharmd online programs. These online doctorate tracks prepare students for licensure and clinical practice, offering a cost-effective route to a high-demand profession in pharmacy.

Best Scientists Citing Nancy F. Olivieri

Trending Scientists

Recently Published Articles